Patents by Inventor Nigel J. Liverton

Nigel J. Liverton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HCV NS3 Protease Inhibitors
    Publication number: 20100298210
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections.
    Type: Application
    Filed: October 19, 2007
    Publication date: November 25, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca, Maria Emilia Di Francesco, Marco Pompei
  • HCV NS3 Protease Inhibitors
    Publication number: 20100286185
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 23, 2007
    Publication date: November 11, 2010
    Inventors: Nigel J Liverton, Joseph P. Vacca, John A. McCauley, Joseph J. Romano, Michael T. Rudo
  • Macrocyclic Compounds As Antiviral Agents
    Publication number: 20100183551
    Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Application
    Filed: July 17, 2008
    Publication date: July 22, 2010
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley, John W. Butcher, Marcello Di Filippo, Maria Emilia Di Francesco, Marco Ferrara, Joseph J. Romano, Michael T. Rudd
  • HCV NS3 Protease Inhibitors
    Publication number: 20100099695
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 23, 2007
    Publication date: April 22, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Maria Emilia Di Francesco, Marco Ferrara, Kevin F. Gilbert, Steven Harper, John A. McCauley, Charles A. McIntyre, Alessia Petrocchi, Marco Pompei, Joseph J. Romano, Michael T. Rudd, John W. Butcher, M. Katharine Holloway
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20100093779
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 22, 2007
    Publication date: April 15, 2010
    Inventors: Nigel J. Liverton, Joseph P. Vacca, John A. McCauley, Joseph J. Romano, Michael T. Rudd
  • Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors
    Publication number: 20100029666
    Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
    Type: Application
    Filed: July 17, 2009
    Publication date: February 4, 2010
    Inventors: Steven Harper, Vincenzo Summa, Nigel J. Liverton, John A. McCauley
  • 3-fluoro-piperidines as NMDA/NR2B antagonists
    Patent number: 7592360
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: September 22, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, Christopher F. Claiborne, David A. Claremon, John A. McCauley
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20090124661
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: December 1, 2008
    Publication date: May 14, 2009
    Applicant: MERCK & CO., INC.
    Inventors: M. Katharine HOLLOWAY, Nigel J. LIVERTON, Steven W. LUDMERER, John A. MCCAULEY, David B. OLSEN, Michael T. RUDD, Joseph P. VACCA, Charles J. MCINTYRE
  • HCV NS3 protease inhibitors
    Publication number: 20090075869
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: April 28, 2006
    Publication date: March 19, 2009
    Inventors: M. Katharine Holloway, Nigel J. Liverton, Steven W. Ludmerer, John A. McCauley, David Olsen, Michael T. Rudd, Joseph P. Vacca
  • HCV NS3 protease inhibitors
    Patent number: 7470664
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: December 30, 2008
    Assignee: Merck & Co., Inc.
    Inventors: M. Katharine Holloway, Nigel J. Liverton, Steven W. Ludmerer, John A. McCauley, David B. Olsen, Michael T. Rudd, Joseph P. Vacca, Charles J. McIntyre
  • N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
    Patent number: 7259157
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: August 21, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, John W. Butcher, Charles McIntyre, Christopher F. Claiborne, David A. Claremon, John A. McCauley, Joseph J. Romano, Wayne Thompson, Peter M. Munson
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    Patent number: 7217716
    Abstract: Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: May 15, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, David A. Claremon, Brian E. Libby, John W. Butcher, John A. McCauley, Nigel J. Liverton, Peter M. Munson, Kevin T. Nguyen, Brian Phillips, Wayne Thompson
  • (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
    Patent number: 7196095
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: March 27, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Richard Beresis, Richard Berger, Steven L. Colletti, James B. Doherty, Dennis D. Feng, Gui-Bai Liang, Dennis M. Schmatz, Xiaoxia Qian, David A. Claremon, Nigel J. Liverton, Charles J. McIntyre, Ernest W. Kovacs
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    Patent number: 7053089
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: May 30, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, John W. Butcher, David A. Claremon, Brian E. Libby, Nigel J. Liverton, Peter M. Munson, Kevin T. Nguyen, Brian Phillips, Wayne Thompson, John A. McCauley
  • Isoquinolinone potassium channels inhibitors
    Patent number: 6870055
    Abstract: The present invention concerns certain isoquinolinone compounds and their utility as inhibitors of voltage-dependent potassium channels or currents, such as Kv1.5 and IKur, that could serve as targets for the treatment of cardiac arrhythmias especially atrial arrhythmias. The present invention also provide a method for treating or preventing conditions which respond to the inhibition of potassium channels or currents, such as cardiac arrhythmias and more especially atrial arrhythmias. The present invention further includes pharmaceutical formulations and a process of making a pharmaceutical composition comprising a compound of certain isoquinolinone or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms, and stereoisomers thereof, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: March 22, 2005
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Charles J. McIntyre, Nigel J. Liverton
  • Radioligand and binding assay
    Patent number: 6838291
    Abstract: The present invention is directed to the radioligand compound, [35S]-radiolabeled (+)-N-[1?-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydoxyspiro[2H-1-benzopyran-2,4?-piperidin]-6-yl]methanesulfonamide. Also within the scope of this invention is a method for identifying compounds that bind to the IKr channel, and may have antiarrhythmic activity.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: January 4, 2005
    Assignee: Merck & Co., Inc.
    Inventors: John W. Butcher, David A. Claremon, Thomas M. Connolly, Jerzy Karczewski, Kenneth S. Koblan, Matthew J. Kostura, Nigel J. Liverton, Dennis C. Dean, David G. Melillo
  • N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
    Publication number: 20040209889
    Abstract: Compounds represented by Formula (I): (I)or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Application
    Filed: July 29, 2003
    Publication date: October 21, 2004
    Inventors: Christopher F Claiborne, David A Claremon, Brian E Libby, John W Butcher, John A McCauley, Nigel J Liverton, Peter M Munson, Kevin T Nguyen, Brian Phillips, Wayne Thompson
  • (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
    Publication number: 20040176396
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis.
    Type: Application
    Filed: November 12, 2003
    Publication date: September 9, 2004
    Inventors: Tesfaye Biftu, Richard Beresis, Richard Berger, Steven L Coletti, James B Doherty, Dennis D Feng, Gui-Bai Liang, Dennis M Schmatz, Xiaoxia Qian, David A Claremon, Nigel J Liverton, Charles J McIntyre, Ernest W Kovacs
  • Substituted imidazoles having cytokine inhibitory activity
    Patent number: 6767908
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which may be useful for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: July 27, 2004
    Assignee: Merck & Co., Inc
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Isoquinolinone potassium channels inhibitors
    Publication number: 20040044030
    Abstract: The present invention concerns certain isoquinolinone compounds and their utility as inhibitors of voltage-dependent potassium channels or currents, such as Kv1.5 and IKur, that could serve as targets for the treatment of cardiac arrhythmias especially atrial arrhythmias. The present invention also provide a method for treating or preventing conditions which respond to the inhibition of potassium channels or currents, such as cardiac arrhythmias and more especially atrial arrhythmias. The present invention further includes pharmaceutical formulations and a process of making a pharmaceutical composition comprising a compound of certain isoquinolinone or its pharmaceutically acceptable salts, hydrates, solvates, crystal forms, and stereoisomers thereof, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: February 25, 2003
    Publication date: March 4, 2004
    Inventors: David A Claremon, Charles J McIntyre, Nigel J Liverton